Literature DB >> 28944170

Implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: an updated systematic review and meta-analysis of outcomes and complications.

Nelson Wang1,2, Ashleigh Xie1, Richard Tjahjono1, David H Tian1, Steven Phan1,2, Tristan D Yan1,2, Pietro Bajona3,4, Kevin Phan1,2.   

Abstract

BACKGROUND: Since the introduction of the implantable cardioverter-defibrillator (ICD) in patients with hypertrophic cardiomyopathy (HCM), the incidence of sudden cardiac death (SCD) has been significantly reduced. Given its widespread use, it is important to identify the outcomes associated with ICD use in patients with HCM. The present paper is a systematic review and meta-analysis of the rates of appropriate and inappropriate interventions, mortality, and device complications in HCM patients with an ICD.
METHODS: We conducted a systematic review and meta-analysis on 27 studies reporting outcomes and complications after ICD implantation in patients with HCM. ICD interventions, device complications, and mortality were extracted for analysis.
RESULTS: A total of 3,797 patients with HCM and ICD implantation were included (mean age, 44.5 years; 63% male), of which 83% of patients had an ICD for primary prevention of SCD. The cardiac mortality was 0.9% (95% CI: 0.7-1.3) per year and non-cardiac mortality was 0.8% (95% CI: 0.6-1.2) per year. Annualized appropriate intervention rate was 4.8% and annualized inappropriate intervention was 4.9%. The annual incidence of lead malfunction, lead displacement and infection was 1.4%, 1.3%, and 1.1%, respectively.
CONCLUSIONS: ICD use in patients with HCM produces low rates of cardiac and non-cardiac mortality, and an appropriate intervention rate of 4.8% per year. However, moderate rates of inappropriate intervention and device complications warrant careful patient selection in order to optimize the risk to benefit ratio in this select group of patients.

Entities:  

Keywords:  Implantable cardioverter-defibrillator (ICD); hypertrophic cardiomyopathy (HCM); meta-analysis

Year:  2017        PMID: 28944170      PMCID: PMC5602202          DOI: 10.21037/acs.2017.07.05

Source DB:  PubMed          Journal:  Ann Cardiothorac Surg        ISSN: 2225-319X


  46 in total

1.  Risk Markers and Appropriate Implantable Defibrillator Therapy in Hypertrophic Cardiomyopathy.

Authors:  Peter Magnusson; Fredrik Gadler; Per Liv; Stellan Mörner
Journal:  Pacing Clin Electrophysiol       Date:  2016-01-21       Impact factor: 1.976

2.  Hypertrophic cardiomyopathy: role of the implantable cardioverter-defibrillator.

Authors:  J Primo; P Geelen; J Brugada; A L Filho; L Mont; F Wellens; M Valentino; P Brugada
Journal:  J Am Coll Cardiol       Date:  1998-04       Impact factor: 24.094

3.  Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy: patient outcomes, rate of appropriate and inappropriate interventions, and complications.

Authors:  Pieter A Vriesendorp; Arend F L Schinkel; Johan Van Cleemput; Rik Willems; Luc J L M Jordaens; Dominic A M J Theuns; Marjon A van Slegtenhorst; Thomy J de Ravel; Folkert J ten Cate; Michelle Michels
Journal:  Am Heart J       Date:  2013-07-16       Impact factor: 4.749

Review 4.  Outcome and complications after implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: systematic review and meta-analysis.

Authors:  Arend F L Schinkel; Pieter A Vriesendorp; Eric J G Sijbrands; Luc J L M Jordaens; Folkert J ten Cate; Michelle Michels
Journal:  Circ Heart Fail       Date:  2012-07-20       Impact factor: 8.790

5.  The frequency and incremental cost of major complications among medicare beneficiaries receiving implantable cardioverter-defibrillators.

Authors:  Matthew R Reynolds; David J Cohen; Aaron D Kugelmass; Phillip P Brown; Edmund R Becker; Steven D Culler; April W Simon
Journal:  J Am Coll Cardiol       Date:  2006-05-30       Impact factor: 24.094

6.  Risk stratification and outcome of patients with hypertrophic cardiomyopathy >=60 years of age.

Authors:  Barry J Maron; Ethan J Rowin; Susan A Casey; Tammy S Haas; Raymond H M Chan; James E Udelson; Ross F Garberich; John R Lesser; Evan Appelbaum; Warren J Manning; Martin S Maron
Journal:  Circulation       Date:  2012-12-30       Impact factor: 29.690

7.  Myocardial fibrosis severity on cardiac magnetic resonance imaging predicts sustained arrhythmic events in hypertrophic cardiomyopathy.

Authors:  Christian Prinz; Maria Schwarz; Ivan Ilic; Kai Thorsten Laser; Roman Lehmann; Eva-Maria Prinz; Thomas Bitter; Jürgen Vogt; Frank van Buuren; Nikola Bogunovic; Dieter Horstkotte; Lothar Faber
Journal:  Can J Cardiol       Date:  2012-06-30       Impact factor: 5.223

8.  Gender differences in procedure-related adverse events in patients receiving implantable cardioverter-defibrillator therapy.

Authors:  Pamela N Peterson; Stacie L Daugherty; Yongfei Wang; Humberto J Vidaillet; Paul A Heidenreich; Jeptha P Curtis; Frederick A Masoudi
Journal:  Circulation       Date:  2009-02-16       Impact factor: 29.690

9.  Rapid Device-Detected Nonsustained Ventricular Tachycardia in the Risk Stratification of Hypertrophic Cardiomyopathy.

Authors:  Karthik Viswanathan; Adrian M Suszko; Moloy DAS; Nicholas Jackson; Michael Gollob; Douglas Cameron; Danna Spears; Anna Woo; Harry Rakowski; Mamta Khurana; Vijay S Chauhan
Journal:  Pacing Clin Electrophysiol       Date:  2016-05-04       Impact factor: 1.976

10.  Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy.

Authors:  Frank A Cuoco; William H Spencer; Valerian L Fernandes; Christopher D Nielsen; Sherif Nagueh; J Lacy Sturdivant; Robert B Leman; J Marcus Wharton; Michael R Gold
Journal:  J Am Coll Cardiol       Date:  2008-11-18       Impact factor: 24.094

View more
  9 in total

1.  Recommendations of the current guidelines for implantable cardioverter-defibrillator implantation in patients with hypertrophic cardiomyopathy: Debate still exists.

Authors:  Arya Aminorroaya; Ali Vasheghani-Farahani; Farzad Masoudkabir; Pegah Roayaei
Journal:  J Interv Card Electrophysiol       Date:  2020-07-25       Impact factor: 1.900

Review 2.  Review on sudden death risk reduction after septal reduction therapies in hypertrophic obstructive cardiomyopathy.

Authors:  Angelos G Rigopoulos; Muhammad Ali; Elena Abate; Marios Matiakis; Hannes Melnyk; Sophie Mavrogeni; Dionyssios Leftheriotis; Boris Bigalke; Michel Noutsias
Journal:  Heart Fail Rev       Date:  2019-05       Impact factor: 4.214

Review 3.  Machine Learning in Arrhythmia and Electrophysiology.

Authors:  Natalia A Trayanova; Dan M Popescu; Julie K Shade
Journal:  Circ Res       Date:  2021-02-18       Impact factor: 17.367

4.  EvaLuation Using Cardiac Insertable Devices And TelephonE in Hypertrophic Cardiomyopathy (ELUCIDATE HCM)-rationale and design: a prospective observational study on incidence of arrhythmias in Sweden.

Authors:  Peter Magnusson; Stellan Mörner
Journal:  BMJ Open       Date:  2017-12-12       Impact factor: 2.692

Review 5.  Implantable cardioverter-defibrillator in hypertrophic cardiomyopathy.

Authors:  Diego Jimenez Sanchez; Ignacio Fernández Lozano
Journal:  Glob Cardiol Sci Pract       Date:  2018-08-12

6.  Bluetooth-Enabled Implantable Cardiac Monitors and Two-Way Smartphone Communication for Patients With Hypertrophic Cardiomyopathy.

Authors:  Sina Safabakhsh; Darson Du; Janet Liew; Jeremy Parker; Cheryl McIlroy; Elina Khasanova; Praveen Indraratna; Philipp Blanke; Jonathon Leipsic; Jason G Andrade; Matthew T Bennett; Nathaniel M Hawkins; Shantabanu Chakrabarti; John Yeung; Marc W Deyell; Andrew D Krahn; Robert Moss; Kevin Ong; Zachary Laksman
Journal:  CJC Open       Date:  2021-11-11

Review 7.  Arrhythmia Monitoring for Risk Stratification in Hypertrophic Cardiomyopathy.

Authors:  Darson Du; Christopher O Y Li; Kevin Ong; Ashkan Parsa; Adaya Weissler-Snir; Jeffrey B Geske; Zachary Laksman
Journal:  CJC Open       Date:  2022-01-07

8.  Case report: Removal of a subcutaneous implantable cardiac defibrillator in a pediatric patient with hypertrophic cardiomyopathy after a septal myectomy. Insights on current indications of type of ICD in children with hypertrophic cardiomyopathy and left ventricular tract obstruction.

Authors:  Paola Dolader; Iosune Alegria; Patricia Martínez Olorón; Joaquin Fernandez-Doblas; Ferran Gran; Ferran Roses-Noguer
Journal:  Front Pediatr       Date:  2022-09-14       Impact factor: 3.569

9.  EvaLuation Using Cardiac Insertable Devices And TelephonE in Hypertrophic Cardiomyopathy (ELUCIDATE HCM): A prospective observational study on incidence of arrhythmias.

Authors:  Peter Magnusson; Stellan Mörner
Journal:  J Cardiovasc Electrophysiol       Date:  2020-11-04       Impact factor: 2.942

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.